Prospective, Multicenter Clinical Study of Microvascular Decompression for Hemifacial Spasm. Issue 4 (19th January 2021)

• Record Type: Journal Article
• Authors: Mizobuchi, Yoshifumi; Nagahiro, Shinji; Kondo, Akinori; Arita, Kazunori; Date, Isao; Fujii, Yukihiko; Fujimaki, Takamitsu; Hanaya, Ryosuke; Hasegawa, Mitsuhiro; Hatayama, Toru; Hongo, Kazuhiro; Inoue, Tooru; Kasuya, Hidetoshi; Kobayashi, Masahito; Kohmura, Eiji; Matsushima, Toshio; Masuoka, Jun; Morita, Akio; Munemoto, Shigeru; Nishizawa, Shigeru; Okayama, Yoshihiro; Sato, Kimitoshi; Shigeno, Taku; Shimano, Hiroshi; Takeshima, Hideo; Tanabe, Hideki; Yamakami, Iwao
• Is Part Of: Neurosurgery. Volume 88:Issue 4(2021)
• Page Start: 846
• Page End: 854
• Publication Date: 2021-01-19
• Subjects: Hemifacial spasm -- Microvascular decompression -- Elderly patients; Nervous system -- Surgery -- Periodicals; 617.48005
• DOI: 10.1093/neuros/nyaa549
• Languages: English
• ISSNs: 0148-396X

Abstract

Abstract: BACKGROUND: Microvascular decompression (MVD) is the most effective procedure for hemifacial spasm (HFS). MVD results from nonspecialized or low-volume institutes are not always reliable. Most studies on MVD for HFS are retrospective and single centered; to the best of our knowledge, no prospective, multicenter studies exist. OBJECTIVE: To evaluate short- and long-term outcomes and complications in patients who underwent MVD for HFS in specialized Japanese institutions, in this multicenter, prospective, cohort study. METHODS: Included patients had undergone MVD for HFS in study centers between April 2012 and March 2015. Patients' postoperative grade of involuntary movements and complications were recorded postoperatively at 7 d (short-term) and at 1 (mid-term) and 3 (long-term) yr. RESULTS: A total of 486 patients (150 men, 336 women; mean age 53.9 yr with 181 patients over 60 yr) were enrolled during the study period. Neuromonitoring was used in 96.3% of the cases. The complete cure rate of symptom relief, mortality rate, and complication rate at short-term follow-up were 70.6%, 0%, and 15%, respectively. The long-term follow-up was completed by 463 patients (95.3%); the complete cure rate of symptom relief and complication rate were 87.1% and 3.0%, respectively. CONCLUSION: Our study revealed that under expert guidance and intraoperative neuromonitoring, the long-term curative effect rate of MVD for HFS is high, while complications are uncommon and usually transient. Our results indicate that MVD is an effective and safe treatment for patients with HFS, including elderly patients. Graphical Abstract: